- Home
- TRDA vs LAB Comparison
TRDA vs LAB Comparison
Compare TRDA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- LAB
- Stock Information
- Founded
- TRDA 2016
- LAB 1999
- Country
- TRDA United States
- LAB United States
- Employees
- TRDA N/A
- LAB N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- TRDA Health Care
- LAB Industrials
- Exchange
- TRDA Nasdaq
- LAB Nasdaq
- Market Cap
- TRDA 264.4M
- LAB 504.2M
- IPO Year
- TRDA 2021
- LAB 2011
- Fundamental
- Price
- TRDA $6.78
- LAB $1.24
- Analyst Decision
- TRDA Strong Buy
- LAB Buy
- Analyst Count
- TRDA 3
- LAB 2
- Target Price
- TRDA $25.67
- LAB $2.50
- AVG Volume (30 Days)
- TRDA 187.5K
- LAB 1.6M
- Earning Date
- TRDA 11-06-2025
- LAB 11-04-2025
- Dividend Yield
- TRDA N/A
- LAB N/A
- EPS Growth
- TRDA N/A
- LAB N/A
- EPS
- TRDA N/A
- LAB N/A
- Revenue
- TRDA $79,476,000.00
- LAB $172,271,000.00
- Revenue This Year
- TRDA N/A
- LAB N/A
- Revenue Next Year
- TRDA N/A
- LAB N/A
- P/E Ratio
- TRDA N/A
- LAB N/A
- Revenue Growth
- TRDA N/A
- LAB 76.33
- 52 Week Low
- TRDA $4.93
- LAB $0.92
- 52 Week High
- TRDA $21.79
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- TRDA 57.18
- LAB 45.85
- Support Level
- TRDA $6.60
- LAB $1.12
- Resistance Level
- TRDA $7.54
- LAB $1.25
- Average True Range (ATR)
- TRDA 0.42
- LAB 0.09
- MACD
- TRDA 0.03
- LAB -0.01
- Stochastic Oscillator
- TRDA 58.86
- LAB 34.29
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.